Page 184 | Certara

Publication

Modeling and Predicting Drug Pharmacokinetics in Patients with Renal Impairment

Current guidance issued by the US FDA to assess the impact of renal impairment on…

CertaraMarch 1, 2011

Publication

Resurgence in the Use of Physiologically-based Pharmacokinetic Models in Pediatric Clinical Pharmacology: Parallel Shift in Incorporating the Knowledge of Biological Elements and Increased Applicability to Drug Development and Clinical Practice

This study had two primary aims: (i) To describe an example of the development work…

CertaraMarch 1, 2011

Knowledge Base

Blood or Plasma? Which Should You Assay for Drug Concentration?

Explore blood vs. plasma drug concentration assays. Learn their differences, relationships, and impact on accurate…

CertaraFebruary 19, 2011

Blog Knowledge Base

Why Should You Evaluate Dose Proportionality?

Dose proportionality is a common phrase used pharmacokinetics. Early in the pre-clinical development process, we…

CertaraFebruary 17, 2011

Knowledge Base

What is the Difference Between PK and TK?

Explore the key differences between pharmacokinetics (PK) and toxicokinetics (TK), their roles in drug development,…

CertaraFebruary 15, 2011

Knowledge Base

Why are PK Parameters Lognormally Distributed?

The statistical analysis of pharmacokinetic parameters is often overlooked and not always well understood. The…

CertaraFebruary 10, 2011

Knowledge Base

What are Direct and Indirect Pharmacodynamic Models?

When constructing pharmacodynamic (PD) models, you will often encounter the adjectives “direct” and “indirect” describing…

CertaraFebruary 8, 2011

Knowledge Base

What is Modeling and Simulation?

I am currently attending a short conference on modeling and simulation in pediatric clinical pharmacology,…

CertaraFebruary 1, 2011

Publication

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer.…

CertaraFebruary 1, 2011

Publication

Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by Use of a Stable Isotope in Patients with Epilepsy

The anticonvulsant properties of phenytoin (PHT) were discovered in 1938. Since then, it has been…

CertaraFebruary 1, 2011

Modeling and Predicting Drug Pharmacokinetics in Patients with Renal Impairment

Resurgence in the Use of Physiologically-based Pharmacokinetic Models in Pediatric Clinical Pharmacology: Parallel Shift in Incorporating the Knowledge of Biological Elements and Increased Applicability to Drug Development and Clinical Practice

Blood or Plasma? Which Should You Assay for Drug Concentration?

Why Should You Evaluate Dose Proportionality?

What is the Difference Between PK and TK?

Why are PK Parameters Lognormally Distributed?

What are Direct and Indirect Pharmacodynamic Models?

What is Modeling and Simulation?

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by Use of a Stable Isotope in Patients with Epilepsy

Newsletter sign up

Quick links

Solutions

Contact